Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: Lazertinib, Itraconazole, Rifampin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Glaucoma, Retinal Disease, Healthy
Interventions: KOWA OCT Bi-µ, Optovue iVue 100; Device
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Menstrual Migraine (MM) Headaches
Interventions: Frovatriptan, Usual Care; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 21
States / cities: Stratford, Connecticut • Clearwater, Florida • Jacksonville, Florida + 18 more

Conditions: Delay Discounting
Interventions: Sequenced Recall of Digits--Auditory, Sequenced Reverse Recall of Digits--Auditory, Sequenced Recall of Words--Visual, Verbal Memory--Visual; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 40 Years to 60 Years
Enrollment: 680 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: Throat Swab; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 1 Day to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hereditary Disease, Genetic Predisposition to Disease
Interventions: Whole Genome Sequencing; Genetic
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Months and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: PF-07817883, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer Study
Interventions: ALG-055009; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Biological Availability
Interventions: Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets, Zavegepant 4 x 25mg enteric coated soft gel capsule; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stroke
Interventions: Hip Hop Stroke educational program, Nutrition Education program; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 7 Years and older
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: MEDI6012, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Hydrochlorothiazide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: LY03005; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: AMRA(r) Researcher Image reconstruction software, MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.), MRI: Research pulse sequences (Device Manufacturer: NIH), MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH), Bluetooth-enabled glucometer, Remote tailored-to-place coaching (TPC), Standard remote coaching (SRC), Run-in physical-activity monitoring, Ambulatory blood-pressure monitor, Polysomnography equipment; Device · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Tremor
Interventions: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Boca Raton, Florida • Farmington Hills, Michigan • Kirkland, Washington

Conditions: Iron Overload, Excessive Body Iron Burden
Interventions: R2*-UTE, R2*-GRE, Liver biopsy; Device · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Gout
Interventions: RDEA3170 10 mg, allopurinol 300 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Pain, Intractable Pain, Low Back Pain, Chronic Low-back Pain, Chronic Leg Pain, Leg Pain
Interventions: Boston Scientific WaveWriter Alpha™ SCS Systems; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Greenwood, Colorado • Clermont, Florida • New Orleans, Louisiana + 4 more

Conditions: Pain, Back, Obesity, Morbid, Type 2 Diabetes
Interventions: Research electrode; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: new software sequences, FIESTA and Vibrant-DE and IDEAL; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

An Assessment of Cognitive Improvement Training Among Mid-life Individuals

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

Effect of Intervention to Improve Stroke Recognition

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

A Relative Bioavailability Food Effect Study of LY03005

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Massive Iron Deposit Assessment

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control

Brown Adipose Tissue Activation by Spinal Cord Stimulation

Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)